{"Symbol": "AAPG", "AssetType": "Common Stock", "Name": "Ascentage Pharma Group International", "Description": "Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.", "CIK": "None", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "SUZHOU INDUSTRIAL PARK, SUZHOU, CHINA, 215000", "OfficialSite": "https://www.ascentage.cn", "FiscalYearEnd": "December", "LatestQuarter": "2025-06-30", "MarketCapitalization": "2228368000", "EBITDA": "-1044163008", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.281", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-2.1", "RevenuePerShareTTM": "4.78", "ProfitMargin": "-2.968", "OperatingMarginTTM": "-2.37", "ReturnOnAssetsTTM": "-0.228", "ReturnOnEquityTTM": "-1.597", "RevenueTTM": "390603000", "GrossProfitTTM": "354927000", "DilutedEPSTTM": "-2.1", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.716", "AnalystTargetPrice": "45.71", "AnalystRatingStrongBuy": "2", "AnalystRatingBuy": "5", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "5.7", "PriceToBookRatio": "22.99", "EVToRevenue": "40.06", "EVToEBITDA": "-", "Beta": "0.883", "52WeekHigh": "48.45", "52WeekLow": "17.55", "50DayMovingAverage": "26.98", "200DayMovingAverage": "33.29", "SharesOutstanding": "92963000", "SharesFloat": "263846000", "PercentInsiders": "0.000", "PercentInstitutions": "0.070", "DividendDate": "None", "ExDividendDate": "None"}